Journal of Clinical Oncology
Articles in this Issue
Outcomes of conversion surgery after immune checkpoint inhibitor-based combination therapy in initially unresectable hepatocellular carcinoma: A retrospective cohort study.
2607 Background: Hepatocellular carcinoma (HCC) has a high incidence rate and is often asymptomatic in its early stages. Combination therapies using immun...
Comparisons of survival outcomes of antibody-drug-conjugates in metastatic breast cancer: A network meta-analysis.
e15003 Background: Antibody-drug conjugates (ADCs) have shown substantial promise as therapies for metastatic breast cancer (mBC). However, direct compari...
Initial results of MC200710 investigating therapeutic vaccine (PDS0101) alone or with pembrolizumab prior to surgery or radiation therapy for locally advanced HPV associated oropharyngeal carcinoma, a phase 2 window of opportunity trial.
6061 Background: PDS0101 is a T cell stimulating immunotherapy (therapeutic vaccine) targeting HPV16. The combination of P...
Crisis within a crisis: A CDC WONDER analysis of the pandemic's impact on cancer and cardiovascular mortality.
e23336 Background: Cancer and cardiovascular disease (CVD) are leading global causes of mortality, often coexisting and worsening outcomes. This study exa...
Clinical activity of immune checkpoint blockade in advanced perivascular epithelioid cell neoplasms (PEComas): A retrospective single center study.
11553 Background: Perivascular epithelioid cell tumors (PEComas) are rare mesenchymal neoplasms with limited therapeutic options. While therapies targetin...
Factors influencing surgical treatment of adenoid cystic carcinoma of the head and neck: A National Cancer Database analysis.
e18150 Background: Adenoid cystic carcinoma (ACC) is a rare malignancy that accounts for 1% of all head and neck malignancies and 10% of salivary gland ca...
Assessing the impact of race and sex on oral squamous cell carcinoma clinical presentation.
e18066 Background: Oral squamous cell carcinoma (OSCC) is the seventh most common cancer worldwide, accounting for 4.5% of new cases. Risk factors include...
Genomic characterization of baseline and post-progression tumors in IMmotion010, a randomized, phase 3 study of adjuvant (adj) atezolizumab (atezo) vs placebo (pbo) in patients (pts) with high-risk localized renal cell carcinoma (RCC).
4510 Background: Although adj atezo did not prolong disease-free survival (DFS) in the IMmotion010 trial, accompanying studies identified post-nephrectomy...
Clinical outcomes of tepotinib and immune checkpoint inhibitor therapy for MET exon 14 skipping NSCLC: A multicentric retrospective analysis.
8631 Background: The VISION study demonstrated that tepotinib, a MET inhibitor, is effective against MET exon 14 (METex14) skipping NSCLC, but the clinica...
Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): First results of overall survival (OS) from CheckMate 577.
4000 Background: At 24.4-month (mo) median follow-up, adjuvant nivolumab demonstrated a statistically significant and clinically meaningful improvement in...
Glucagon-like peptide-1 receptor agonists and the risk of chemotherapy-induced peripheral neuropathy in patients with diabetes: A real-world study.
12133 Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a prevalent condition that significantly affects quality of life in patients with c...
Addressing domestic abuse in cancer care: Developing and piloting a specialized intervention for healthcare professionals.
e13549 Background: Over 20% of people in England and Wales have lifetime experience of domestic abuse (DA)—i.e. family violence. Healthcare-based DA inter...
Association of HIPEC response in ovarian cancer with PI3K/RAS/Notch gene signatures: A whole transcriptomic analysis of U.S. and French HIPEC treated ovarian cancer patients.
5569 Background: Hyperthermic intraperitoneal chemotherapy (HIPEC) is associated with improved overall survival in Stage III epithelial ovarian cancer (EO...
Clinical trial access in patients with pancreatic cancer (PC): A Pancreatic Cancer Action Network (PanCAN) patient survey.
e23174 Background: PC is the third leading cause of cancer-related deaths in the US with a five-year survival rate of only 13%. Limited data suggest low r...
Factors associated with survival following relapse of high-risk neuroblastoma: A study from the International Neuroblastoma Risk Group (INRG) Data Commons.
10052 Background: Outcomes for high-risk neuroblastoma (HR-NBL) following relapse are poor, although there is a paucity of data on overall survival post-r...
Socioeconomic- and insurance-based inequities in Oncotype DX testing and score-guided treatment.
1589 Background: Personalized approaches to breast cancer treatment are increasingly guided by expensive, lab-based genomic testing like Oncotype DX (ODX)...
Competencies for practicing medical oncology with common sense: A global curricula review.
9018 Background: The Common Sense Oncology (CSO) movement advocates for high-quality, patient-centered cancer care by emphasizing evidence-based, patient-...
Hematopoietic stem cell transplant in multiple myeloma: An analysis of mortality, costs, and patient characteristics.
e19556 Background: Multiple myeloma (MM) is a clonal plasma cell neoplasm projected to affect approximately 36,000 people and result in 12,000 deaths in t...
Association between obesity biomarkers and breast cancer risk in Nigeria.
e12556 Background: Obesity is an important risk factor for breast cancer, but current strategies have not addressed it for primary prevention of breast ca...
Assessing treatment outcomes of enfortumab vedotin dose reduction in metastatic bladder cancer.
4576 Background: Enfortumab Vedotin (EV), an antibody drug conjugate targeting Nectin-4, has emerged as first-line treatment for advanced Urothelial Carci...
The importance of algorithms when determining homologous recombination deficiency status in ovarian tumors.
e15166 Background: Ovarian tumors with homologous recombination deficiency (HRD) respond better to PARP inhibitor and platinum-based chemotherapy treatmen...
Co-expressing pattern of multiple biomakers and dynamic change of Claudin18.2 expression after systemic chemotherapy in advanced gastric cancer.
4037 Background: Gastric cancer (GC) is a heterogeneous disease classified by Lauren classification and TCGA’s four molecular subtypes. Targeting Claudin...
Cancer patients’ perspectives: A qualitative study of reasons for subcutaneous preference vs intravenous treatment.
e23124 Background: Oncology therapeutics are increasingly available via subcutaneous (SC) administration. While previous studies demonstrate a patient pre...
Plasma-guided adaptive first-line chemoimmunotherapy for non-small cell lung cancer (NSCLC).
8515 Background: There is clinical uncertainty as to which patients with advanced/metastatic NSCLC require first-line treatment with chemoimmunotherapy (C...
Efficacy and safety of neoadjuvant zimberelimab and cetuximab plus nab-paclitaxel and cisplatin (NeoZCPC) for resectable locally advanced hypopharyngeal/laryngeal squamous cell carcinoma: An open-label, single-arm phase II clinical trial.
e18095 Background: Locally advanced hypopharyngeal/laryngeal squamous cell carcinoma (LA-HLSCC) patients necessitate novel therapeutic approaches to impro...